



**HAL**  
open science

## Plasma levels of hsa-miR-152-3p are associated with diabetic nephropathy in patients with type 2 diabetes

Maguelonne Roux, Claire Perret, Eva Feigerlova, Badreddine Mohand Oumoussa, Pierre-Jean Saulnier, Carole Proust, David-Alexandre Trégouët, Samy Hadjadj

### ► To cite this version:

Maguelonne Roux, Claire Perret, Eva Feigerlova, Badreddine Mohand Oumoussa, Pierre-Jean Saulnier, et al.. Plasma levels of hsa-miR-152-3p are associated with diabetic nephropathy in patients with type 2 diabetes. *Nephrology Dialysis Transplantation*, 2018, 33 (12), pp.2201-2207. 10.1093/ndt/gfx367 . hal-02272317

**HAL Id: hal-02272317**

<https://hal.sorbonne-universite.fr/hal-02272317v1>

Submitted on 27 Aug 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## **Plasma levels of miR-152-3p are associated with diabetic nephropathy in patients with type 2**

### **diabetes**

Maguelonne Roux MSc<sup>1,2</sup>, Claire Perret Msc<sup>1,2</sup>, Eva Feigerlova MD, PhD<sup>3,4,5,6</sup>, Badreddine Mohand Oumoussa BSc<sup>7</sup>, Pierre-Jean Saulnier MD, PhD<sup>3,4,5,6</sup>, Carole Proust Msc<sup>1,2</sup>, David-Alexandre Trégouët PhD<sup>1,2\*</sup>, Samy Hadjadj MD, PhD<sup>3,4,5,6,\*</sup>.

<sup>1</sup>Sorbonne Universités, UPMC Université Paris 06, INSERM UMR-S 1166, F-75013, Paris, France

<sup>2</sup>ICAN Institute for Cardiometabolism and Nutrition, Paris, France

<sup>3</sup>CHU de Poitiers, Service d'Endocrinologie, Poitiers, France

<sup>4</sup>Université de Poitiers, UFR Médecine Pharmacie, Poitiers, France

<sup>5</sup>CHU de Poitiers, Centre d'Investigation Clinique, Poitiers, France

<sup>6</sup>INSERM, CIC 1402 & U1082, Poitiers, France

<sup>7</sup> Sorbonne Universités, UPMC Université Paris 06, Platform Post Genomic Pitié-Salpêtrière, Paris, France

**\* These authors equally contributed as last authors**

**Corresponding author:** David-Alexandre Trégouët  
Faculté de médecine Pierre & Marie Curie  
91, boulevard de l'hôpital  
75013 Paris  
France  
tel: +33 1 40 77 96 86  
fax: + 33 1 40 77 97 28  
e-mail: [david.tregouet@upmc.fr](mailto:david.tregouet@upmc.fr)

## **ABSTRACT**

### **Background**

MiRNAs are small non-coding RNAs participating in genes post-transcriptional regulation. Their key role in modulating the susceptibility to human diseases is now widely recognized, in particular in the context of cardiometabolic disorders. The aim of the present study was to identify miRNAs associated with diabetic nephropathy (DN) in patients with type 2 diabetes (T2D).

### **Methods**

A next generation sequencing-based miRNA profiling was performed in a case-control study for DN in plasma samples of 23 T2D patients with DN (cases) and 23 T2D without (controls). The main associations were confirmed using qRT-PCR and tested for replication in an independent case-control collection of 100 T2D patients, 50 with DN and 50 without.

### **Results**

From the 381 known mature miRNAs that were found highly expressed in the discovery samples, we observed and replicated an association between increased plasma levels of hsa-miR-152-3p and DN ( $p = 4.03 \cdot 10^{-4}$  in the combined samples). Hsa-miR-152-3p plasma levels were further found to be positively correlated ( $p = 0.003$ ) to plasma osmolarity, a surrogate marker for solute carrier net activity, whose regulation is controlled by several genes including *SLC5A3*, one of the predicted targets of hsa-miR-152-3p.

### **Conclusions**

We observed strong evidence for the association of hsa-miR-152-3p plasma levels and DN in patients with T2D confirming an association previously observed in patients with T1D.

**KEY WORDS:** Circulating microRNA; microRNA-Sequencing; Type 2 diabetes; Diabetic nephropathy; biomarkers.

## **INTRODUCTION**

Diabetes is considered as the leading cause of end-stage renal failure, contributing to more than one-third of all end-stage renal disease based on the 2016 report of United States Renal Data System <sup>1</sup>. Diabetic nephropathy (DN) remains incompletely understood and occurs in 30 to 40% of diabetic patients <sup>2</sup>, and even in patients with good glycemic control <sup>3</sup>. Abnormalities in several signaling pathways and cytokines have been demonstrated to contribute to DN development, including the renin-angiotensin system, reactive species of oxygen, endoplasmic reticulum stress, pro-inflammatory cytokines and formation of advanced glycation end-products <sup>4,5</sup>.

Urinary albumin excretion is widely used as a non-invasive marker for DN although it does not fully reflect the disease process <sup>6</sup>. Histological abnormalities may be present before the detection of microalbuminuria. Similarly, some patients have decreased glomerular filtration rate (GFR) despite normoalbuminuria <sup>7,8</sup>. This phenotype seems to be rather common in type 2 diabetes (T2DM) <sup>9</sup>, challenging traditional classification of DN <sup>10</sup>. An important effort is currently undertaken to identify innovative biomarkers of diabetic nephropathy, as illustrated by the recent grant from the UE on biomarkers of DN ([https://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-05-06/1662621-c5\\_imi2\\_c5\\_text\\_9\\_july\\_2015\\_en.pdf](https://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-05-06/1662621-c5_imi2_c5_text_9_july_2015_en.pdf)).

Recently, post-transcriptional regulation of mRNA has emerged as a major mechanism modulating gene expression. Non-coding RNAs such as microRNAs (miRNAs) participate in regulating mRNA stability and aberrant miRNA expression has been shown to account for renal fibrosis and podocyte injury <sup>11,12</sup>. In response to various pathophysiological conditions, miRNAs can be released by cells into different extracellular fluids, including blood and could serve as biomarkers of diverse diseases including diabetes and its complications. Circulating miRNAs are more stable due to protection from endogenous RNase activity through their incorporation into lipoprotein complexes or microvesicles such as exosomes <sup>13-15</sup>. Recent reports have demonstrated distinct profiles of miRNAs and exosomal

miRNAs in plasma and urine samples across various stages of diabetic nephropathy<sup>16-20</sup>.

Widely used techniques for identification of differentially expressed miRNAs, such as miRNA microarrays, suffer from a low accuracy due to low specificity of probe hybridization and variable sensitivity to detect less abundant miRNAs. The next-generation sequencing has a high-resolution potential, even though limited data is available in the relevant literature on its use as a discovery-based approach to identify enriched or dysregulated miRNAs in DN. The aim of the present study was to perform a comprehensive sequencing of plasma miRNAs in subjects with T2DM to identify candidate miRNAs for DN.

## **MATERIAL & METHODS**

### **Study populations**

Studied participants were patients with T2DM selected from the cross-sectional DIAB2NEPHROGENE study, which aimed to compare genetic and non-genetic determinants of renal complications in T2D patients. This study design was previously reported<sup>21,22</sup>. The DIAB2NEPHROGENE study was approved by the Poitiers University Ethics Committee and was in accordance with the Helsinki Declaration of 1975, as revised in 2000. All participants gave written informed consent.

Cases were patients with T2DM and DN defined as increased urinary albumin (micro or macroalbuminuria) with or without altered renal function (defined as estimated glomerular filtration rate eGFR below 60 ml/min per 1.73m<sup>2</sup>, according to CKD-EPI equation<sup>23</sup>) and no clinical and/or biological suspicion of non-diabetic kidney disease. Micro and macroalbuminuria were diagnosed according to urinary albumin determined on two out of three sterile urine collections:

microalbuminuria range  $\geq 20$  - 199 mg/l or 30-299 mg/24 hrs, and macroalbuminuria range  $\geq 200$  mg/l or 300 mg/24 hrs. Controls were patients with T2DM with normal urinary albumin (range  $< 20$  mg/l or 30 mg/24 hrs) and eGFR above 60 ml/min/1.73m<sup>2</sup>.

DN patients and controls were matched for the following criteria: recruiting center, age (+/- 5 years), sex. Although not strictly considered as a matching criterion, a special effort was made to have cases and controls not largely differing for diabetic retinopathy (absent, simple, severe non-proliferative or proliferative retinopathy) in order to focus on DN rather than on microvascular risk in general. Biological samples were stored at -80°C at the CHU Poitiers biobanking facility (CRB Poitiers BB0033-00068) until use (first freeze-thawing cycle).

### **Biological determinations**

Biological determinations of classical biological variables are briefly reported here : HbA1c by HPLC (Adams A1c HA-8160 analyzer; Menarini, Florence, Italy); creatinine by colorimetry on an automated analyzer (Kone Optima; Thermo Clinical LabSystems, Vantaa, Finland) for plasma determinations and on a Hitachi 911 automatic analyzer (Roche Diagnostics, Meylan, France) for urinary determinations; urinary albumin by nephelometry on a Modular System P (Roche Diagnostics GmbH) and osmolarity by the measure of the point of congelation of aqueous solutions with an automatic micro-osmometer (Fisher Bioblock Scientific, Illkirch, France).

### **Experimental protocol for miRNA sequencing**

Plasma miRNA profiling was conducted in a sample of 46 T2D patients, half of which being patients with DN and the remaining half being free of DN. Total RNA containing miRNA was extracted from EDTA plasma sample (400 µl) with Qiagen miRNeasy Serum/Plasma kit (Qiagen, Hilden, Germany). Plasma miRNA libraries were then prepared from 6µl of total RNA using the NEBNext Multiplex Small RNA Library Prep Set for Illumina (New England Biolabs France, Evry) according to manufacturer's instructions with a specific dilution of adaptors to 1/10 and 15 cycles for PCR amplification. Specific small RNAs bands were then selected by a 3-steps optimized AMPure XP Beads (Agencourt Bioscience Corporation, Beverly, Massachusetts, USA) protocol in 96-well plate

(200 µl), without QIAQuick PCR purification: 1- a 1.5X AMPure XP beads purification step was first performed on 100 µl of amplified library to remove smaller fragments and the bead product was resuspended with H<sub>2</sub>O (42 µl); 2- 1.1X AMPure XP beads were added to the first purification products (42 µl); 3- After discarding beads with the smallest fragments, the resulting supernatant was kept and purified with 1.8X AMPure XP beads. The beads product, resuspended in H<sub>2</sub>O (15 µl), served as the final purified library. Two plasma samples were analyzed in duplicate. A pool of equal quantity of 24 purified libraries was constructed, each library being tagged with a different index. Two pools of 24 libraries were constituted in order to analyze the 46 plasma samples, each pool being loaded on 2 lanes of a rapid flowcell. A 55bp single read sequencing of miRNAs pool libraries was performed on an Illumina HiSeq 1500 instrument (Illumina, San Diego, California, USA) at the Post-Genomic Platform of the Pitié-Salpêtrière Hospital.

### **miRNA sequencing data analysis**

After demultiplexing, reads that did not pass Illumina filters were removed with `fastq_illumina_filter`<sup>24</sup>. `Cutadapt`<sup>25</sup> was used to trim 3' and 5' adapters and remove low-quality bases (quality <28) from the 3' and 5' ends. Reads with a length between 15 and 30 bases, i.e. reads that could correspond to miRNAs, were selected for further alignment. `Bowtie v1.1.1`<sup>26</sup> was used to align reads against the Homo Sapiens mature miRNA sequences from the miRBase 21 database<sup>27</sup>. Only reads that uniquely aligned without any mismatch were kept for the present study. miRNA abundance was expressed as the number of reads (i.e counts) that aligned to a given miRNA. To avoid any background noise due to very low expressed miRNAs, only miRNAs with counts higher than 10 in more than 5 subjects were kept for analysis. To normalize abundances, we first applied the size factor correction as proposed in the `Deseq` method<sup>28</sup> followed by the application of the variance stabilizing transformation<sup>29</sup>. Impact of the normalization procedure can be evaluated by inspecting the miRNA expression profiles that are more comparable across samples after normalization (**Supplementary**

**Figure S1**), without impacting on the reproducibility of the technical replicates (**Supplementary Figure S2**). For the subsequent differential analysis, replicates with the lower count variability were used.

Association between detected miRNAs and DN was performed using linear regression analysis adjusted for age, sex, and counts of 3 let7 controls (let7d/7g/7i) miRNAs in order to avoid any uncontrolled bias in libraries preparation<sup>30</sup>. Beforehand, miRNAs were normalized using the normal inverse quantile transformation<sup>31</sup>.

### **qRT-PCR validation**

Candidate miRNAs showing suggestive statistical evidence for association with DN in the miRNA sequencing analysis were re-quantified for technical validation by qRT-PCR after a new extraction. miRNA qRT-PCR was performed by specific TaqMan miRNA assays using the TaqMan microRNA Reverse Transcription kit and TaqMan Universal PCR Master Mix no UNG (Thermo Fisher Scientific, Waltham, USA) according to the manufacturer's instructions (**Supplementary Methods**). MiRNA levels were normalized to the miRNA content of a mix of 3 miRNAs -let7d, let7g and let7i- and the relative miRNA levels were calculated using the  $2^{-\Delta CT}$  method. The same methodologies were applied to the candidate miRNAs further measured in an independent sample of 100 T2D patients composed of 50 patients with DN and 50 without. Linear regression analysis, adjusting for age and sex, were employed to test for the association between the qRT-PCR miRNA levels and DN status, in the discovery and replication samples, separately.

## **RESULTS**

### **miRNA identification results**

Before pre-processing steps, the average number of reads per sample was  $10.5 \cdot 10^6$ , ranging from  $7.5 \cdot 10^6$  to  $13.8 \cdot 10^6$ . After quality controls, a per-sample average of 64.67% of reads (min = 46.55%, max



= 86.59%) was kept for alignment analysis. The percentage of reads that uniquely matched to human mature miRNAs ranged from 2.4% to 16.44%, with a mean of 6.47%, which led to the detection in the 46 studied plasma samples of 1,424 known mature miRNAs. From these miRNAs, 384 miRNAs (including the 3 housekeeping miRNAs serving as positive controls - see Methods) were considered as expressed and entered into the differential expression analysis with respect to DN.

### **Discovery step**

Clinical and biological characteristics of cases and controls in both the discovery and replication cohorts are presented in **Table 1**. Differential expression analysis between cases and controls, with the full list of results given in **Supplementary Table S3**, did not reveal any significant association that satisfied the statistical threshold of  $1.3 \cdot 10^{-4}$  corresponding to the Bonferroni correction for the number of tested miRNAs ( $n = 381$ ). The lowest p-value was observed at  $p = 1.57 \cdot 10^{-3}$  for hsa-miR-362-5p. Nevertheless, 4 miRNAs exhibited a marginal association with DN at  $p < 0.01$ . Boxplot representation of their expression levels in cases and controls are shown in **Figure 1**. Among these 4 miRNAs, three were over-expressed in cases compared to controls, hsa-miR-362-5p ( $p = 1.57 \cdot 10^{-3}$ ), hsa-miR-152-3p ( $p = 4.34 \cdot 10^{-3}$ ) and hsa-miR-196b-5p ( $p = 4.47 \cdot 10^{-3}$ ) while the remaining hsa-miR-140-3p ( $p = 6.28 \cdot 10^{-3}$ ) demonstrated opposite pattern of association. These 4 miRNAs were selected for further technical validation.

### **Technical validation**

We checked the consistency between miRNA levels measurements obtained by sequencing and qRT-PCR for the 4 miRNAs with p-values  $< 0.01$ , selected at the discovery step. The correlation between qRT-PCR levels and sequencing data was satisfactory for hsa-miR-152-3p ( $r = 0.64$ ), hsa-miR-196b-5p ( $r = 0.53$ ) and hsa-miR-362-5p ( $r = 0.42$ ) but not for hsa-miR-140.3p ( $r = 0.19$ ).

Nevertheless, using the qRT-PCR measurements, only the association of hsa-miR-152-3p with DN

was still significant ( $p = 0.002$ ) with increased expression in cases compared to controls (**Table 2**), leading us to select hsa-miR-152-3p for replication in an independent sample.

### **Replication step**

Following these observations, the association of miRNA hsa-miR-152-3p with DN was tested in another sample of 100 T2D patients made of 50 cases and 50 controls, whose characteristics are detailed in **Table 1**. Consistently with the results observed in the discovery cohort, the hsa-miR-152-3p showed increased plasma levels in DN patients compared to non-DN patients (0.061 vs 0.055) with association reaching borderline significance ( $p = 0.053$ ) (**Table 2**).

In the combined discovery and replication samples, the statistical evidence between hsa-miR-152-3p plasma levels and DN was  $p = 4.03 \cdot 10^{-4}$ .

### **Intermediate phenotype**

Interestingly, the identified hsa-miR-152-3p is computationally predicted<sup>32</sup> to target the *SLC5A3* gene previously suspected to be involved in acute renal failure<sup>33</sup> of which DN is an important contributing factor<sup>34</sup>. As the SLC5A3 protein is involved in the regulation of osmolarity, we examined the relationship between hsa-miR-152-3p plasma levels and plasma osmolarity, which is a surrogate marker for solute carrier net activity. Plasma osmolarity did not differ between cases and controls (**Table 1**). In the total samples, we observed a positive correlation ( $r = 0.26$ ,  $p = 0.003$ ) between hsa-miR-152-3p plasma levels and plasma osmolarity (**Supplementary Figure S4**). This correlation was observed both in the discovery ( $r = 0.20$ ) and the replication ( $r = 0.28$ ) samples, and in cases ( $r = 0.16$ ) and controls ( $r = 0.24$ ).

Of note, we did not evidence any correlation between hsa-miR-152-3p plasma levels and urinary albumin/creatinine ratio nor eGFR (data not shown).

## **DISCUSSION**

To our knowledge, the pilot work reported here is the first to apply an agnostic next-generation sequencing technology to plasma samples of T2D patients in order to identify candidate miRNAs for DN. In addition, our study included a technical validation step of the main results observed in a discovery phase as well as a statistical replication in an independent sample. This work revealed that hsa-miR-152-3p plasma levels were increased in DN cases compared to controls, both in the discovery and replication cohorts. Interestingly, this miRNA had been previously found associated with DN in type 1 diabetes patients by a candidate miRNA approach<sup>35</sup>. These results strongly suggest that the hsa-miR-152-3p is involved in the DN pathophysiology in the population of patients with diabetes. Computational prediction includes SLC5A3 gene as one of the hsa-miR-152-3p's targets. *SLC5A3* encodes the SMIT1 (Sodium/myo-inositol transporter) protein, an inositol transported contributing to maintaining the osmotic balance in different tissues/organs, including the kidney<sup>36</sup>, whose evidence for its role in diabetes-associated metabolism is accumulating<sup>33,37,38</sup>. Besides, we evidenced an association of hsa-miR-152-3p plasma levels with plasma osmolarity, an intermediate phenotype for the activity of solute carrier transporters genes, including SLC5A3. Of note, SLC5A3 has been reported to associate with acute renal failure<sup>33</sup>. Unfortunately, we were not able to detect SLC5A3 mRNA in our T2D plasma samples (**Supplementary Methods**) which prevented us from testing any association between DN, SLC5A3 mRNA and hsa-miR-152-3p levels. We did not observe any correlation between hsa-miR-152-3p plasma levels and markers of DN (eg eGFR, urinary ACR) suggesting the identification of a potential pathway not involved in glomerular pathway but more likely related to tubular ion transfer. A recent study<sup>39</sup> has highlighted the role of hsa-miR-152-3p in the hepatic regulation of glucose metabolism through a mechanism involving the PTEN pathway. Of note, Kato *et al*<sup>40</sup> have demonstrated in mice that the PTEN pathway is also a key target for several glomerular miRNAs associated with DN. In the same mice model, glomerular levels of hsa-miR-152-

3p were found elevated in diabetic animals compared to controls<sup>40</sup>. Of note the main glomerular DN-associated miRNA identified in their work, miR-379, was not among those showing strong association with DN in our plasma samples (not shown data). Finally, obesity, a risk factor for chronic kidney disease<sup>41</sup> has been reported to associate with increased serum levels of hsa-miR-152-3p in non-diabetic patients<sup>42</sup>. We thus questioned if obesity could be a confounding factor between hsa-miR-152-3p and DN. In our study population with T2DM, we did not observe any association between hsa-miR-152-3p and body mass index (data not shown).

Several limitations must be acknowledged. We were not able to find any significant association between miRNA and DN that passed the study-wise statistical threshold in our discovery cohort. This is likely to be a power issue due to the small size of the T2D samples processed for miRNA sequencing. As an illustration, the power of our discovery cohort to detect, at the  $p = 1.3 \cdot 10^{-4}$  threshold, any association observed with the hsa-miR-152-3p was only 50%. We were also limited by the available quantity of mRNA material we could have access to in order to validate all suggestive associations observed in the miRNA sequencing phase. As a consequence, we cannot exclude we have missed some additional miRNAs that could associate with DN. In addition, a very stringent bioinformatics pipeline was applied to miRNA sequenced data where mismatch and multiple alignments were not taken into account in this study. This could have limited our chance to discover additional relevant miRNAs. Finally, even though cases and controls were well-matched for important determinants of DN such as age, gender<sup>43</sup> but also diabetic retinopathy<sup>44</sup>, the phenotype between discovery and replication steps was slightly different for cases, with only proteinuric patients in the discovery and a combination of microalbuminuric and proteinuric patients in the replication population. In that way, the replication step could be considered as a replication and an extension step rather than a mere replication with strictly concordant inclusion criteria. These phenotypic differences might explain why the hsa-miR-152-3p plasma levels tend to be higher in cases from the discovery group than in those from the replication phase. However, we found no confounding factors for the

association between hsa-miR-152-3p levels and patients' characteristics (see **Table 1**). The lower association observed in the replication compared to the discovery step could also be due to the well-known winner curse effect<sup>45,46</sup>.

Although our research strategy was not aiming to validate candidate miRNAs, we were able to find 23 miRNAs with nominal p-values <0.05 (**Supplementary Table S3**) and some of them including hsa-miR-132p, hsa-miR-192-5p and hsa-miR-326 were already described in previous work<sup>35</sup>. The association observed with hsa-miR-132p was however in the opposite direction as that observed in type 1 patients. Finally, our research design was cross-sectional and led to the identification of an association between DN and plasma levels of hsa-miR-152-3p. In this context, an important caveat must be kept in mind as hsa-miR-152-3p dysregulation could be a consequence of DN rather than causally implicated. The positive correlation between plasma osmolarity and hsa-miR-152-3p plasma levels adds support to the predicted relation between hsa-miR-152-3p and *SLC5A3* regulation. But the lack of association of plasma osmolarity and DN tends to exclude that the association of hsa-miR-152-3p plasma levels with DN could be mediated via a direct influence on plasma osmolarity.

In conclusion, our pilot study identified the hsa-miR-152-3p as a miRNA that associate with the risk of DN in patients affected with T2D and that can be measured in plasma material. This miRNA has been previously shown to associate with DN in a cross-sectional study in patients with T1D. Large prospective studies are now required to validate plasma hsa-miR-152-3p as a biomarker for DN and to establish its prognostic value beyond urinary albumin. In addition, functional experiments are also mandatory to deeply characterize the underlying pathophysiological mechanisms.

## **ACKNOWLEDGEMENTS**

We wish to thank all of the patients and physicians who took part in the DIAB2NEPHROGENE study (see **Supplementary Note**).

We also wish to thank E Migault, M Grosdenier and S Brishoual (Inserm CIC1402, Poitiers) and the

CRB Poitiers (BB0033-00068) staff for their help with data collection, biobanking and sample handling.

**CONFLICT OF INTEREST STATEMENT** None declared.

The results presented in this paper have not been published previously in whole or part, except in abstract format.

### **AUTHORS' CONTRIBUTION**

MR was in charge of all bioinformatic and statistical analyses of the biological data under the supervision of DAT. MR drafted the manuscript that was further reviewed by EF, DAT and SH. miRNA extraction and libraries preparation for sequencing were conducted by CPe. EF, PJS and CPr participated to clinical and biological data collection and measurements. Sequencing of the miRNA data was performed by BMO. The study was designed by DAT and SH. All authors approved the submitted version.

### **FUNDING**

M.R was financially supported by the Fondation pour la Recherche Médicale and the GENMED Laboratory of Excellence on Medical Genomics (ANR-10-LABX-0013). Data analysis was performed using the C2BIG computing cluster, funded by the Région Ile de France, Pierre and Marie Curie University, and the ICAN Institute for Cardiometabolism and Nutrition (ANR-10-IAHU-05). The DIAB2NEPHROGENE study was supported by grants from PHRC-Poitiers 2004, PHRC-IR 2008, and AFD (Research Grant 2003). The Groupe d'Etude des Maladies Métaboliques et Systémiques (Poitiers, France) also supported the study.

## REFERENCES

1. Annual Data Report. <https://www.usrds.org/adr.aspx>. Accessed May 30, 2017.
2. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. *Diabetologia*. 2006;49(1):11-19. doi:10.1007/s00125-005-0077-3.
3. Zhang L, Krzentowski G, Albert A, Lefèbvre PJ. Factors predictive of nephropathy in DCCT Type 1 diabetic patients with good or poor metabolic control. *Diabet Med J Br Diabet Assoc*. 2003;20(7):580-585.
4. Forbes JM, Cooper ME. Mechanisms of diabetic complications. *Physiol Rev*. 2013;93(1):137-188. doi:10.1152/physrev.00045.2011.
5. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes*. 2005;54(6):1615-1625.
6. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? *Diabetes*. 2000;49(9):1399-1408.
7. Bangstad HJ, Osterby R, Dahl-Jørgensen K, et al. Early glomerulopathy is present in young, type 1 (insulin-dependent) diabetic patients with microalbuminuria. *Diabetologia*. 1993;36(6):523-529.
8. Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. *Diabetes*. 1994;43(11):1358-1364.
9. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. *Diabetes Care*. 2004;27(1):195-200.
10. Mogensen CE, Christensen CK, Vittinghus E. The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy. *Diabetes*. 1983;32(Supplement 2):64-78. doi:10.2337/diab.32.2.S64.
11. Chung ACK, Huang XR, Meng X, Lan HY. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. *J Am Soc Nephrol JASN*. 2010;21(8):1317-1325. doi:10.1681/ASN.2010020134.
12. Lai JY, Luo J, O'Connor C, et al. MicroRNA-21 in glomerular injury. *J Am Soc Nephrol JASN*. 2015;26(4):805-816. doi:10.1681/ASN.2013121274.
13. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci U S A*. 2011;108(12):5003-5008. doi:10.1073/pnas.1019055108.
14. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol*. 2011;13(4):423-433. doi:10.1038/ncb2210.
15. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007;9(6):654-659. doi:10.1038/ncb1596.

16. Argyropoulos C, Wang K, Bernardo J, et al. Urinary microRNA profiling predicts the development of microalbuminuria in patients with type 1 diabetes. *J Clin Med*. 2015;4(7):1498-1517. doi:10.3390/jcm4071498.
17. Barutta F, Tricarico M, Corbelli A, et al. Urinary exosomal microRNAs in incipient diabetic nephropathy. *PloS One*. 2013;8(11):e73798. doi:10.1371/journal.pone.0073798.
18. Delić D, Eisele C, Schmid R, et al. Urinary exosomal miRNA signature in type II diabetic nephropathy patients. *PloS One*. 2016;11(3):e0150154. doi:10.1371/journal.pone.0150154.
19. Glowacki F, Savary G, Gnemmi V, et al. Increased circulating miR-21 levels are associated with kidney fibrosis. *PloS One*. 2013;8(2):e58014. doi:10.1371/journal.pone.0058014.
20. Feigerlová E, Battaglia-Hsu S-F. Role of post-transcriptional regulation of mRNA stability in renal pathophysiology: focus on chronic kidney disease. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2017;31(2):457-468. doi:10.1096/fj.201601087RR.
21. Hadjadj S, Fumeron F, Roussel R, et al. Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. *Diabetes Care*. 2008;31(9):1847-1852. doi:10.2337/dc07-2079.
22. Leveziel N, Ragot S, Gand E, et al. Association between diabetic macular edema and cardiovascular events in type 2 diabetes patients: a multicenter observational study. *Medicine (Baltimore)*. 2015;94(33):e1220. doi:10.1097/MD.0000000000001220.
23. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-612.
24. Illumina CASAVA-1.8 FASTQ Filter. [http://cancan.cshl.edu/labmembers/gordon/fastq\\_illumina\\_filter/](http://cancan.cshl.edu/labmembers/gordon/fastq_illumina_filter/). Accessed September 3, 2015.
25. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal*. 2011;17(1):10-12.
26. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol*. 2009;10(3):R25. doi:10.1186/gb-2009-10-3-r25.
27. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res*. 2014;42(D1):D68-D73. doi:10.1093/nar/gkt1181.
28. Anders S, Huber W. Differential expression analysis for sequence count data. *Genome Biol*. 2010;11(10):R106. doi:10.1186/gb-2010-11-10-r106.
29. Huber W, Heydebreck A von, Sültmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. *Bioinformatics*. 2002;18(suppl 1):S96-S104. doi:10.1093/bioinformatics/18.suppl\_1.S96.
30. Chen X, Liang H, Guan D, et al. A Combination of Let-7d, Let-7g and Let-7i Serves as a Stable



Reference for Normalization of Serum microRNAs. *PLoS ONE*. 2013;8(11):e79652. doi:10.1371/journal.pone.0079652.

31. Peng B, Yu RK, Dehoff KL, Amos CI. Normalizing a large number of quantitative traits using empirical normal quantile transformation. *BMC Proc*. 2007;1 Suppl 1:S156.
32. Agarwal V, Bell GW, Nam J-W, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. *eLife*. 4. doi:10.7554/eLife.05005.
33. Kitamura H, Yamauchi A, Sugiura T, et al. Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat. *Kidney Int*. 1998;53(1):146-153. doi:10.1046/j.1523-1755.1998.00747.x.
34. Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. *N Engl J Med*. 2014;371(1):58-66. doi:10.1056/NEJMra1214243.
35. Bijkerk R, Duijs JMGJ, Khairoun M, et al. Circulating microRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas-kidney transplantation. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2015;15(4):1081-1090. doi:10.1111/ajt.13072.
36. Schneider S. Inositol transport proteins. *FEBS Lett*. 2015;589(10):1049-1058. doi:10.1016/j.febslet.2015.03.012.
37. Li SYT, Cheng STW, Zhang D, Leung PS. Identification and Functional Implications of Sodium Myo-Inositol Cotransporter 1 in Pancreatic  $\beta$ -Cells and Type 2 Diabetes. *Diabetes*. 2017;66(5):1258-1271. doi: 10.2337/db16-0880.
38. Van Steenberghe A, Balteau M, Ginion A, et al. Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. *Sci Rep*. 2017;7:41166. doi: 10.1038/srep41166
39. Wang S, Wang L, Dou L, et al. MicroRNA 152 regulates hepatic glycogenesis by targeting PTEN. *FEBS J*. 2016;283(10):1935-1946. doi:10.1111/febs.13713.
40. Kato M, Wang M, Chen Z, et al. An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy. *Nat Commun*. 2016;7:12864. doi:10.1038/ncomms12864.
41. D'Agati VD, Chagnac A, de Vries APJ, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. *Nat Rev Nephrol*. 2016;12(8):453-471. doi:10.1038/nrneph.2016.75.
42. Wu L, Dai X, Zhan J, et al. Profiling peripheral microRNAs in obesity and type 2 diabetes mellitus. *APMIS Acta Pathol Microbiol Immunol Scand*. 2015;123(7):580-585. doi:10.1111/apm.12389.
43. de Haeclocque A, Ragot S, Slaoui Y, et al. The influence of sex on renal function decline in people with Type 2 diabetes. *Diabet Med J Br Diabet Assoc*. 2014;31(9):1121-1128. doi:10.1111/dme.12478.
44. Hammes H-P, Welp R, Kempe H-P, et al. Risk Factors for Retinopathy and DME in Type 2 Diabetes-Results from the German/Austrian DPV Database. *PloS One*. 2015;10(7):e0132492.

doi:10.1371/journal.pone.0132492.

45. Göring HH, Terwilliger JD, Blangero J. Large upward bias in estimation of locus-specific effects from genomewide scans. *Am J Hum Genet.* 2001;69(6):1357-1369. doi:10.1086/324471.
46. Zhong H, Prentice RL. Correcting “winner’s curse” in odds ratios from genomewide association findings for major complex human diseases. *Genet Epidemiol.* 2010;34(1):78-91. doi:10.1002/gepi.20437.

**Table 1 Characteristics of the study population**

|   | Discovery Sample        |                       | Replication Sample     |                       |
|---|-------------------------|-----------------------|------------------------|-----------------------|
|   | Cases<br>N = 23         | Controls<br>N = 23    | Cases<br>N = 50        | Controls<br>N = 50    |
| Age (years)   | 64.56 (8.35)            | 64.74 (7.29)          | 65.50 (8.11)           | 64.70 (7.65)          |
| Sex (Male/Female)   | 17/6                    | 17/6                  | 37/13                  | 37/13                 |
| eGFR (ml/min/1.73m <sup>2</sup> )   | 50.74 (19.11)           | 82.35<br>(13.24)      | 64.64<br>(22.89)       | 80.04<br>(12.93)      |
| uACR (mg/l/mmol)  | 132.0<br>[26.8 - 189.0] | 0.67<br>[0.47 - 1.13] | 12.8<br>[3.84 - 40.98] | 0.99<br>[0.64 - 1.55] |
| Normo/micro/macroalbuminuria  | 0/0/23                  | 23/0/0                | 0/27/23                | 50/0/0                |
| Diabetic Retinopathy<br>(absent/simple/severe non<br>proliferative/proliferative) | 0/17/2/4                | 2/15/4/2              | 0/31/16/3              | 5/32/8/5              |
| Systolic Blood Pressure (mmHg)  | 164.2<br>(22.83)        | 140.6<br>(18.69)      | 143.6<br>(18.98)       | 136.2<br>(18.03)      |
| Diastolic Blood Pressure (mmHg)   | 83.9<br>(11.73)         | 78.8<br>(8.83)        | 76.1<br>(8.29)         | 75.2<br>(10.74)       |
| BMI (kg.m <sup>-2</sup> )   | 30.88 (5.69)            | 29.75 (5.24)          | 30.67 (5.34)           | 30.53 (6.06)          |
| HbA1c (%)   | 7.77 (1.20)             | 7.70 (1.00)           | 8.11 (1.74)            | 7.78 (1.18)           |
| Known Diabetes duration (years)   | 22.56 (5.83)            | 22.26 (5.16)          | 18.52 (9.06)           | 19.52 (10.04)         |
| Current Smoker (%)  | 0%                      | 13%                   | 17%                    | 6%                    |
| Plasma Osmolarity<br>(mOsm)   | 308.5 (8.29)            | 301.5 (5.07)          | 303.8 (9.12)           | 300.5 (7.52)          |

eGFR: estimated Glomerular Filtration Rate determined according to the CKD EPI formula.

uACR: Urinary albumin:creatinine ratio

Data shown represent mean (standard deviation) except for smoking (% of smokers); sex, albuminuria and diabetic retinopathy (counts); uACR (median [1<sup>st</sup> quartile - 3<sup>rd</sup> quartile]).

**Table 2 Association of hsa-miR-152-3p with DN**

|                | Discovery         |                      |                      | Replication       |                      |                      |
|----------------|-------------------|----------------------|----------------------|-------------------|----------------------|----------------------|
|                | Cases<br>(n = 23) | Controls<br>(n = 23) | P value <sup>a</sup> | Cases<br>(n = 50) | Controls<br>(n = 50) | P value <sup>a</sup> |
| hsa-miR-152-3p | 0.072<br>(0.026)  | 0.052<br>(0.018)     | p = 0.002            | 0.061<br>(0.017)  | 0.055<br>(0.018)     | p = 0.053            |

Shown values correspond to mean (standard deviation) of miRNA levels measured by qRT-PCR and normalized to let7 controls miRNAs using the  $2^{-\Delta CT}$  method. <sup>a</sup>Adjusted for age and sex.

**Figure 1**

**Association of top 4 miRNAs with DN status.**

Boxplot representation of top miRNAs plasma levels in T2D patients with (cases) and without (controls) DN. Association testing was performed on normalized plasma levels adjusted for age, sex, and counts of the 3 controls (let7d, let7g and let7i) miRNAs.

